Vimarsana
Biggest News Aggregation in the World

Solomon Langermann News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Solomon Langermann. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Solomon Langermann Today - Breaking & Trending Today

NextCure and LCB Present Preclinical Data on B7-H4 Antibody Drug Conjugate at AACR 2024 - Vimarsana News

NextCure and LCB Present Preclinical Data on B7-H4 Antibody Drug Conjugate at AACR 2024

Published: April 8, 2024

Poster presentation highlights strong safety and pharmacokinetic profiles for LNCB74BELTSVILLE, Md., April 08, 2024 -- NextCure, Inc. , a clinical-stage biopharmaceutical company committed to...

Source: marketscreener.com
Related Topics:
San DiegoUnited StatesLigachem BiosciencesLegochem BiosciencesLigachem BioscienceTimothy MayerAmerican Association For Cancer ResearchNextcure IncExchange CommissionLegochem Biosciences IncLigachem Biosciences IncCancer ResearchAnnual MeetingSolomon LangermannAntibody Drug ConjugatesChem Biosciences
NextCure Publishes Non-Clinical Data Demonstrating Anti-Siglec-15 Treatment Prevented Bone Loss Due to Immobilization from Acute Spinal Cord Injury - Vimarsana News

NextCure Publishes Non-Clinical Data Demonstrating Anti-Siglec-15 Treatment Prevented Bone Loss Due to Immobilization from Acute Spinal Cord Injury

Published: December 21, 2023

BELTSVILLE, Md., Dec. 21, 2023 -- NextCure, Inc. , a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and...

Source: marketscreener.com
Related Topics:
New YorkUnited StatesWeiping QinTimothy MayerNextcure IncMineral ResearchCord Damage Research CenterExchange CommissionJamesj Peters Veteran Affairs Medical CenterIcahn School Of Medicine At Mount SinaiPamerican Society For BonePrevents Marked Bone LossAcute Spinal Cord Injury Induced ImmobilizationAmerican SocietySolomon LangermannIcahn SchoolMount SinaiSpinal Cord Damage Research CenterVeteran Affairs Medical Center
NextCure Publishes Non-Clinical Data Demonstrating - Vimarsana News

NextCure Publishes Non-Clinical Data Demonstrating

Published: December 21, 2023

BELTSVILLE, Md., Dec. 21, 2023 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and...

Source: globenewswire.com
Related Topics:
New YorkUnited StatesWeiping QinTimothy MayerExchange CommissionIcahn School Of Medicine At Mount SinaiJamesj Peters Veteran Affairs Medical CenterCord Damage Research CenterMineral ResearchPamerican Society For BoneNextcure IncPrevents Marked Bone LossAcute Spinal Cord Injury Induced ImmobilizationAmerican SocietySolomon LangermannIcahn SchoolMount SinaiSpinal Cord Damage Research CenterVeteran Affairs Medical CenterNasdaq Nxtc
Preclinical Data Demonstrate Anti-Siglec-15 Treatment Reduced Bone Loss and Enhanced Bone Quality in Mice with Moderate-to-Severe Osteogenesis Imperfecta (OI) - Vimarsana News

Preclinical Data Demonstrate Anti-Siglec-15 Treatment Reduced Bone Loss and Enhanced Bone Quality in Mice with Moderate-to-Severe Osteogenesis Imperfecta (OI)

Published: October 17, 2023

Data Presented at the 2023 American Society for Bone and Mineral Research Annual MeetingBELTSVILLE, Md., Oct. 17, 2023 -- NextCure, Inc. , a clinical-stage biopharmaceutical company committed to...

Source: marketscreener.com
Related Topics:
United StatesHospital For Special SurgeryNew YorkTimothy MayerCathleen RaggioExchange CommissionMineral ResearchPamerican Society For BoneNextcure IncData PresentedTransform InfraredSolomon LangermannSpecial SurgerySexual DimorphismTreatment EffectAdult MiceModerate To Severe Osteogenesis
A Phase 2 Study of Anti-Siglec-15 Antibody, NC318, in Combination with Pembrolizumab (NCT04699123) Demonstrates Clinical Activity in Patients with Advanced PD-1 Axis Inhibitor Refractory NSCLC - Vimarsana News

A Phase 2 Study of Anti-Siglec-15 Antibody, NC318, in Combination with Pembrolizumab (NCT04699123) Demonstrates Clinical Activity in Patients with Advanced PD-1 Axis Inhibitor Refractory NSCLC

Published: September 12, 2023

• Data presented at the 2023 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer in Singapore BELTSVILLE, Md., Sept. 12, 2023 -- NextCure,...

Source: marketscreener.com
Related Topics:
Timothy MayerLieping ChenRoy HerbstYale Cancer CenterYale School Of MedicineNextcure IncMedicine Medical Oncology At Yale UniversitySpecialized Program Of Research ExcellenceDean For Translational ResearchExchange CommissionChen At Yale UniversityUnited Technologies Corporation Professor In Cancer ResearchYale UniversityLung CancerInternational AssociationSolomon LangermannYale CancerSpecialized ProgramResearch ExcellenceEnsign ProfessorMedical OncologyDeputy DirectorSmilow Cancer HospitalAssistant DeanTranslational Research